All Posts Tagged With: "RX"
(RX) IMS Health Reports Earnings In Line
IMS Health (RX) reported fourth-quarter earnings per share (EPS) of 39 cents, in line with the Zacks Consensus Estimate. However, after adjusting for charges related to restructuring initiatives, asset impairment and others, EPS came in at 52 cents compared to 50 cents in the...
10Feb2010 | vitalstocks | 0 comments | Continued(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Jan2010 | vitalstocks | 0 comments | Continued(RX) IMS Health to be Acquired by Funds Managed by TPG Capital
IMS Health (RX) recently agreed to its acquisition by investment funds managed by TPG Capital (TPG) and the Canada Pension Plan Investment Board (CPPIB) for a total value of $5.2 billion. The Board of Directors approved the decision based on the Transaction Committee recommendation,...
14Nov2009 | vitalstocks | 0 comments | Continued(RX) Big Pharma and Biotech – Industry Outlook
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between...
9Nov2009 | Shawn | 0 comments | Continued(RX) IMS Health Earnings Ahead of Consensus Estimates
This morning, IMS Health (RX) reported third-quarter earnings per share of 40 cents, beating the Zacks Consensus Estimate by 4 cents. However, earnings declined 7% from the year-ago period. Revenues came in at $540.8 million. With clients reining in their spending due to the...
22Oct2009 | vitalstocks | 0 comments | Continued